Platform Clinical Study for Conquering Scleroderma
Status:
Recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test efficacy of different investigational products
(IPs) compared with placebo on the change from baseline to the end of the treatment period at
Week 52 in lung capacity in participants with Interstitial Lung Disease Secondary to Systemic
Sclerosis.